LncRNA dysregulation in DCs can modulate their anti-tumor function by affecting their tumor infiltration, differentiation and metabolism, as well as their ability to cross-prime CD8+ T cell-mediated responses [50]. This evidence concerns the gene CD8A and neoplasm.